Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial by Schwartz, Gregory G., MD, PhD, Bessac, Laurence, MD, Berdan, Lisa G., PA, MHS, Bhatt, Deepak L., MD, MPH, Bittner, Vera, MD, Diaz, Rafael, MD, Goodman, Shaun G., MD, MSc, Hanotin, Corinne, MD, Harrington, Robert A., MD, Jukema, J. Wouter, MD, PhD, Mahaffey, Kenneth W., MD, Moryusef, Angèle, MD, Pordy, Robert, MD, Roe, Matthew T., MD, MPH, Rorick, Tyrus, RN, Sasiela, William J., PhD, Shirodaria, Cheerag, MBBS, Szarek, Michael, PhD, Tamby, Jean-François, MD, Tricoci, Pierluigi, MD, White, Harvey, MBBS, DSc, Zeiher, Andreas, MD, Steg, Philippe Gabriel, MD

Get full text

Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials by Vallejo-Vaz, Antonio J, Ginsberg, Henry N, Davidson, Michael H, Eckel, Robert H, Cannon, Christopher P, Lee, L Veronica, Bessac, Laurence, Pordy, Robert, Letierce, Alexia, Ray, Kausik K

Get full text

Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 OD... by Bays, Harold E., Leiter, Lawrence A., Colhoun, Helen M., Thompson, Desmond, Bessac, Laurence, Pordy, Robert, Toth, Peter P.

Get full text

Inverse Relationship Between Major Adverse Cardiovascular Events and non-High-Density Lipoprotein Cholesterol and Apolipoprotein B in Phase 3 Trials of Alirocumab by Davidson, Michael H., MD, Cannon, Christopher P., MD, Ginsberg, Henry N., MD, Pordy, Robert, MD, Bessac, Laurence, MD, Minini, Pascal, PhD, Eckel, Robert H., MD, Ray, Kausik K., BSc

Get full text

Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control by Ray, Kausik K, Ginsberg, Henry N, Davidson, Michael H, Pordy, Robert, Bessac, Laurence, Minini, Pascal, Eckel, Robert H, Cannon, Christopher P

Get full text

Alirocumab, a Fully Human Monoclonal Antibody to Proprotein Convertase Subtilisin/kexin Type 9: Therapeutic Dosing in Phase 3 Studies by Pordy, Robert, MD, Lecorps, Guillaume, MSc, Bessac, Laurence, MD, Sasiela, William J., PhD, Ginsberg, Henry, MD

Get full text

Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab... by Vallejo-Vaz, Antonio J., Ray, Kausik K., Ginsberg, Henry N., Davidson, Michael H., Eckel, Robert H., Lee, L. Veronica, Bessac, Laurence, Pordy, Robert, Letierce, Alexia, Cannon, Christopher P.

Get full text

RELATIONSHIP BETWEEN PERCENTAGE REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND MAJOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AMONG PATIENTS TREATED WITH STATINS +/- ALI... by Ray, Kausik, Ginsberg, Henry, Davidson, Michael, Pordy, Robert, Bessac, Laurence, Minini, Pascal, Eckel, Robert, Cannon, Christopher

Get full text

RELATIONSHIP BETWEEN MAJOR ADVERSE CARDIOVASCULAR EVENTS AND ACHIEVED LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN PHASE 3 ODYSSEY TRIALS OF ALIROCUMAB VERSUS CONTROL by Cannon, Christopher P, Ginsberg, Henry, Ray, Kausik, Davidson, Michael, Pordy, Robert, Bessac, Laurence, Minini, Pascal, Eckel, Robert

Get full text

LOWER ON-TREATMENT LOW-DENSITY LIPOPROTEIN CHOLESTEROL IS ASSOCIATED WITH LOWER CARDIOVASCULAR RISK IN WOMEN: ANALYSES FROM THE ODYSSEY TRIALS OF ALIROCUMAB VERSUS CONTROL by Vallejo-Vaz, Antonio, Ginsberg, Henry, Davidson, Michael, Eckel, Robert H, Cannon, Christopher, Lee, Veronica, Bessac, Laurence, Pordy, Robert, Letierce, Alexia, Ray, Kausik

Get full text

LOWER ON-TREATMENT LOW-DENSITY LIPOPROTEIN CHOLESTEROL IS ASSOCIATED WITH LOWER CARDIOVASCULAR RISK IN VERY HIGH RISK PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: ANALYSES... by Ray, Kausik Kumar, Vallejo-Vaz, Antonio, Ginsberg, Henry, Davidson, Michael, Eckel, Robert H, Lee, Veronica, Bessac, Laurence, Pordy, Robert, Letierce, Alexia, Cannon, Christopher

Get full text

Alirocumab Treatment Effect on Non-HDL-C: Pooled Analyses of 10 Phase 3 Trials in the ODYSSEY Program by Bays, Harold E., MD, Leiter, Lawrence A, Colhoun, Helen M, Thompson, Desmond, Bessac, Laurence, Pordy, Robert, Toth, Peter P., MD, PhD

Get full text

Usages du droit by Aprile, Sylvie, Audren, Frédéric, Bensimon, Fabrice, Berthereau, Estelle, Bessac-Vaure, Stève, Bogani, Lisa, Bron, Grégoire, Colantonio, Laurent, Delpu, Pierre-Marie, Diaz, Delphine, Edelman, Nicole, El Gammal, Jean, Gelez, Philippe, Guignard, Laurence, Houbre, Gabrielle, Huard, Raymond, Ingold, Alice, Jarrige, François, König, Mareike, Larroche, Emmanuel, Lembré, Stéphane, Lenoir, Joëlle Louise, Lobban, Michael, Loncle, Stéphanie, Malandain, Gilles, Marly, Mathieu, Millet, Audrey, Oualdi, M’hamed, Petiteau, Natalie, Prothero, Iorwerth, Richard, Nathalie, Salomé, Karine, Sapiro, Gisèle, Sauget, Stéphanie, Vaughan, Géraldine, Villerbu, Tangi, Voilliot, Christophe

Get full text